Evidence map›Paper›PMID 38611089›Full record

ArticleCancers2024

Prognostic Value of

Massimiliano Ruscica, Chiara Macchi, Sara Gandini, Debora Macis, Aliana Guerrieri-Gonzaga, Valentina Aristarco, Davide Serrano, Matteo Lazzeroni, Alessandra Stefania Rizzuto, Aurora Gaeta and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Massimiliano RuscicaDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0002-0195-7061
Chiara MacchiDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0002-5919-989X
Sara GandiniDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-1348-4548
Debora MacisDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-0633-2933
Aliana Guerrieri-GonzagaDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0003-1915-1688
Valentina AristarcoDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-4939-6240
Davide SerranoDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-2945-4108
Matteo LazzeroniDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-2162-4002
Alessandra Stefania RizzutoDepartment of Clinical Sciences and Community Health, Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0002-5704-9230
Aurora GaetaDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-4944-7685
Alberto CorsiniDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0002-9912-9482
Marcella GulisanoMedical Oncology, Ospedale S. Bortolo, 36100 Vicenza, Italy.ORCID 0000-0001-5303-2725
Harriet JohanssonDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-4131-2030
Bernardo BonanniDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0003-3589-2128
European Institute of Oncology · ITUniversity of Milan · ITOspedale San Bortolo · IT

Funding

Bank of Italy 2023
6 · The paper itself

Abstract

BACKGROUND AND

aimThe involvement of cholesterol in cancer development remains a topic of debate, and its association with breast cancer has yet to be consistently demonstrated. Considering that circulating cholesterol levels depend on several concomitant processes, we tested the liability of plasma levels of proprotein convertase subtilisin/kexin type 9 (

methodsWithin a prospective randomized breast cancer prevention trial we measured baseline plasma levels of

resultsThe plasmatic

conclusionsIn premenopausal women at risk of early-stage breast cancer,

Indexed as

biomarkerbreast cancerlipidsPCSK9

Identifiers

PMID38611089
PMCPMC11011028
OpenAlexW4393949149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.